Why You Should Add Two Medical Stocks to Your Watch List

By

Medical-StocksThere are still all kinds of earnings results pouring into the marketplace, and a lot of them are modestly decent.

Brand-name companies have mostly reported. There has been some broadening of the positive stock market action into the NASDAQ Composite Index.

The stock market’s breakout certainly was well evidenced by blue chips and transportation stocks. But another sector that has been particularly strong (and safe) is health care.

In medical instruments and supplies, specifically, Becton, Dickinson and Company (NYSE/BDX) reported solid earnings that beat consensus, and the company increased its guidance for the rest of the year. The company has 30,000 employees in over 50 countries.

According to the Franklin Lakes, New Jersey-based company, quarterly revenues grew to $2.0 billion for the second fiscal quarter (ended March 31, 2013). This represented an increase of 3.7% over the comparable quarter, and 4.1% without currency translation.

Company management said that its business confidence is growing and raised its fiscal 2013 full-year guidance.

The company’s stock market chart is featured below:

 bdx-becton-dickinson-and-co

      Chart courtesy of www.StockCharts.com

More than 50% of the company’s revenues come from abroad. International sales in the most recent quarter were $1.2 billion, for a gain of 6.2% comparatively; these numbers reflect strength in the emerging markets, especially in diabetes care products.

Actual quarterly earnings were down a little bit due to a one-time charge. The company reported earnings from continuing operations of $1.39 per diluted share, compared to diluted earnings per share of $1.31, for a 6.1% gain year-over-year, or 7.6% on a foreign currency neutral basis.

But what the stock market was so enthused about was the company’s increased guidance for fiscal 2013.

Being a large-cap blue-chip company, Becton, Dickinson and Co. expects revenue gains of 4.5%–5.0% this fiscal year. Excluding currency translation, earnings per share are expected to increase 8.5%–9.0%.

Like many large-cap companies that broke out on the stock market at the beginning of the year, Becton, Dickinson and Co. has been soaring lately.

On the stock market, the position is not expensively priced, and the company has lots of cash in the bank.

Medical devices and healthcare stocks are sectors that are attractive for long-term portfolios. Demand for healthcare-related services is consistent, but it is very evident that some of the best growth is in the treatment of diabetes and kidney disease.

DaVita HealthCare Partners Inc. (NYSE/DVA) is the powerhouse kidney treatment business. It has increased 758% on the stock market over the last decade and is an earnings machine.

But considering new positions now with the stock market at record highs is unwise. (Read “Is Current Market Action Just the Calm Before the Storm?”)

However, these stocks do offer solid growth potential and would certainly be a lot more attractive if their share prices experienced a meaningful correction.

For sure, the earnings growth is there.

Retire on one hot stock

Presenting Our Top Stock Pick for 2015!

It is one of the leading companies in its industry. With quarterly revenue of $800 million and growing this company is generating over $300 million every three months in free cash flow!

"A Golden Opportunity for Stock Market Investors" is yours FREE when you opt-in to get our daily e-letter Profit Confidential. With Profit Confidential you are receiving the opinions and commentaries of seasoned financial analysts and economists. We analyze the actions of the stock market, precious metals, interest rates, real estate, and other investments so we can tell you what we believe today's financial news will mean for you tomorrow!

Combined, we have over 100 years' experience in analyzing various investment markets. Our analysts include MBAs, BAs, B.Comms, P.Engs, MAs, LLBs...and most importantly, years of experience investing and managing our own money successfully!

To opt-in to our FREE e-letter Profit Confidential and to get your FREE report, "A Golden Opportunity for Stock Market Investors," enter your e-mail address in the box below. You can unsubscribe at any time.

We hate spam as much as you do. Check out our Privacy Policy.

About the Author | Browse Mitchell Clark's Articles

Mitchell Clark is a senior editor at Lombardi Financial, specializing in large- and micro-cap stocks. He’s the editor of a variety of popular Lombardi Financial newsletters, including Micro-Cap Reporter, Income for Life, Biotech Breakthrough Stock Report, and 100% Letter. Mitchell has been with Lombardi Financial for 17 years. He won the Jack Madden Prize in economic history and is a long-time student of equity markets. Prior to joining Lombardi, Mitchell was a stockbroker for a large investment bank. In the... Read Full Bio »

Related Articles

Investors: This Could Send Gold Prices Soaring in 2015
By Michael Lombardi

Poll

For the rest of 2015, what's your take on oil?

View Results

Loading ... Loading ...
Profit Confidential
×
107.20.34.173
From: Michael Lombardi, MBA
Subject: Gold: The Stock Contrarian Investors’ Best Play of the Decade

Read this message